|
Oct 3
|
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at IDWeek 2024
|
|
Aug 27
|
SCYNEXIS to Participate in H. C. Wainwright 26th Annual Global Investment Conference
|
|
Jul 23
|
SCYNEXIS to Receive $10 Million Milestone Payment from GSK Triggered by Delivery of Completed FURI, CARES and NATURE Clinical Study Reports
|
|
May 8
|
SCYNEXIS Reports First Quarter 2024 Financial Results and Provides Corporate Update
|
|
May 8
|
Investors in SCYNEXIS (NASDAQ:SCYX) have unfortunately lost 87% over the last five years
|
|
Apr 30
|
SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global, Formerly ECCMID)
|
|
Apr 9
|
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
|
|
Mar 28
|
SCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate Update
|
|
Jan 30
|
SCYNEXIS to Participate in Guggenheim’s 6th Annual Biotechnology Conference
|
|
Jan 29
|
SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 against Mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis Conference
|
|
Jan 5
|
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Advances Against Aspergillosis and Mucormycosis Conference, January 25 – 27, in Milan, Italy
|
|
Nov 30
|
Shareholders in SCYNEXIS (NASDAQ:SCYX) are in the red if they invested five years ago
|
|
Nov 27
|
11 Cheapest Stocks With Biggest Upside
|
|
Nov 13
|
SCYNEXIS Reports Third Quarter 2023 Financial Results and Provides Corporate Update
|
|
Aug 14
|
SCYNEXIS Reports Second Quarter 2023 Financial Results and Provides Corporate Update
|
|
Aug 11
|
10 Best Fast Growing Penny Stocks to Buy Now
|